BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin’s enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones.
Read the full article: BioMarin Announces Completion of Acquisition of Inozyme //
Source: https://www.prnewswire.com/news-releases/biomarin-announces-completion-of-acquisition-of-inozyme-302495683.html